Call our 24 hours, seven days a week helpline at 800.272.3900

24/7 Helpline 800.272.3900

Dr. Joanne Pike Named to National Alzheimer's Project Act Advisory Council

Dr. Joanne Pike Named to National Alzheimer's Project Act Advisory Council
Share or Print this page
Share or Print this page
October 20, 2021
Share or Print this page
Chief Strategy Officer of the Alzheimer’s Association to Join HHS Council; National Early Stage Advisory Joe Montminy Also Named to Council
WASHINGTON, D.C., October 20, 2021 — The Department of Health and Human Services (HHS) has announced the appointment of Joanne Pike, Dr.PH, to the National Alzheimer’s Project Act (NAPA) Advisory Council. Dr. Pike serves as Chief Strategy Officer of the Alzheimer’s Association, overseeing the Association’s strategic plan to advance risk reduction, care and support, research, advocacy, diversity, equity and inclusion, concern and awareness and fundraising.
The NAPA Advisory Council is a public-private collaboration that provides information and recommendations to HHS on policy solutions that will improve the health outcomes and lives of those living with Alzheimer’s and other dementias, as well as their caregivers.
“It’s an honor to join the NAPA Advisory Council to help ensure our nation’s government programs are meeting the needs of those living with Alzheimer’s and all other dementia,” said Dr. Pike. “In the 10 years since NAPA was unanimously passed by Congress, establishing this critical council, we have seen extraordinary progress. I’m honored to join the council as we continue our work to improve the lives of everyone impacted by Alzheimer’s and all other dementia, addressing risk factors, advancing treatments, and improving access to critical and effective care and support.”
The Alzheimer’s Association and AIM worked with Congressional champions to develop and build bipartisan support for NAPA, resulting in the first National Plan to Address Alzheimer’s Disease, with the first goal of preventing and effectively treating Alzheimer’s by 2025. The Advisory Council was also created by that law. Alzheimer’s research funding has seen a more than seven-fold increase since the passage of the NAPA. With strong funding, scientists are able to work at a more rapid pace to advance basic disease knowledge, explore ways to reduce risk, uncover new biomarkers for early diagnosis and drug targeting, and develop potential treatments.
In addition to Dr. Pike, HHS appointed Joe Montminy, a member of the Alzheimer’s Association early stage advisory group to the Advisory Council. Montminy has been a vocal advocate since his diagnosis, lending his time to raise awareness and speak out on behalf of individuals living with Alzheimer’s and all other dementia. He also serves on the Massachusetts/New Hampshire Alzheimer's Association Board of Directors.
Today more than 6 million Americans are living with Alzheimer's disease, and 11 million more providing unpaid care. And, at a cost of $355 billion a year, Alzheimer's is the most expensive disease in the nation.

Alzheimer's Association

The Alzheimer's Association leads the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia®. For more information, visit or call the 24/7 Helpline at 800.272.3900.

Alzheimer’s Impact Movement

The Alzheimer's Impact Movement (AIM) is a separately incorporated advocacy affiliate of the Alzheimer's Association. AIM works to develop and advance policies to overcome Alzheimer's disease through increased investment in research, enhanced care and improved support. For more information, visit

Keep Up With Alzheimer’s News and Events